UK PHILANTHROPISTS SIMONE AND PAUL COMMINS DONATED GBP 1oo,ooo FOR DELTAREX-G CANCER RESEARCH
Hope and husband Sean on Santa Monica Beach, California
Graphic illustration of DeltaRex-G vector. The DeltaRex-G vector has a navigational GPS system (A), for tracking down and binding to abnormal Signature (Sig) proteins in the tumor microenvironment (B), and encodes a CCNG1 inhibitor gene for killing cancer cells (C).
The Aveni Foundation mission is to expedite development of gene-targeted technologies for cancer and other unmet medical needs.
Working towards a cure for advanced sarcoma
Who: Simone and Paul Commins, a UK businessman who has curated a successful trading career, donated GBP 100,000 to Aveni Foundation for DeltaRex-G cancer research. This was inspired by their niece, Hope Stringer, with advanced sarcoma who wishes to receive DeltaRex-G, a tumor-targeted gene therapy that has gained Expanded Access Authorization from the USFDA for the treatment of patients with advanced sarcoma and pancreatic cancer.
DeltaRex-G has induced long term survival (>10 years) in patients with chemotherapy failed Stage 4 soft tissue sarcoma, osteosarcoma, pancreatic cancer, breast cancer and B cell lymphoma (Chawla et al., Anticancer Res. 43: 2383-2391 (2023). doi:10.21873/anticanres.16406).
DeltaRex-G was created over a decade ago by local scientists Drs. Erlinda M. Gordon and Frederick L. Hall. It is ONLY available at the Sarcoma Oncology Center in Santa Monica CA. DeltaRex-G is supplied by the Aveni Foundation, a 501(c)(3) public charity founded by Dr. Gordon in 2018, that raises money through generous benefactors to make the medicine. It is not available through drug or insurance companies.
Note Best: This press release is in compliance with HIPAA.
To donate: Click on the DONATE button at www.avenifoundation.org
For further information, please visit our websites: www.avenifoundation.org, contact Dr.Gordon at egordon@avenifoundation.org or egordon@sarcomaoncology.com.
Erlinda Gordon
Aveni Foundation
+1 818-726-3278
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
